The leadership of Kidney Cancer has disclosed the following information in keeping with the journal's disclosure policy.
Primo N. Lara, Jr., MD, Editor-in-Chief
Consultant or Advisory Role: Janssen (personal), Calithera (institutional)
Institutional Research Funding: Janssen Biotech, Merck, Pharmacyclics, Incyte, Taiho Pharmaceutical
Peter Mulders, MD, PhD, Editor-in-Chief
Speaker Honoraria: MSD,TELIX, AstraZeneca, Astellas
Consultant: Telix, Synthon
Clinical Trials: Telix, MSD
Neeraj Agarwal, MD, Associate Editor
Consultant or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Lily, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, Gilead Sciences
Institutional Research Funding: Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas
Laurence Albiges, MD, PhD, Associate Editor
Speaker Honoraria: Astellas, AstraZeneca, Bellerophon, BMS, Corvus Pharmaceuticals, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Springer Healthcare
Clinical Trials: Pfizer, BMS, Ipsen
Other: Roche, Exelixis
Axel Bex, MD, PhD, Associate Editor
Consulting or Advisory Role: Bristol-Myers Squibb (institutional), Roche/Genentech (institutional)
Research Funding: Pfizer (institutional)
Clinical Trials: Steering committee member BMS adjuvant trial, Steering committee member Roche adjuvant trial
Other Research Support: Pfizer educational restricted grant for a investigator initiated neoadjuvant trial
Enrique Grande, MD, Associate Editor
Speaker Honoraria, Advisory Roles, Funding of Continuous Medical Education: Adacap, AMGEN, Angelini, Astellas, AstraZeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Esteve, Eusa Pharma, Genetracer, GSK, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Thermo Fisher Scientific
Research Grants: Astellas, AstraZeneca, IPSEN, Lexicon, Merck KGaA, MTEM/Threshold, Nanostring Technologies, Pfizer, Roche
Leadership Roles in Medical Societies: ENETS, GETNE and GETHI
Private Healthcare Provider: MD Anderson Cancer Center Madrid (workplace)
Commercial Medical Education Provider: Universidad Europea de Madrid (UEM), Universidad CEU Cardenal Herrera, Universidad Rey Juan Carlos, Oncinfo
Stocks or Ownership Interest: None
Viktor Grünwald, MD, Associate Editor
Stock and Other Ownership Interests: MSD,Bristol-Myers Squibb, AstraZeneca, Seagen, Genmab,
Honoraria: Bristol-Myers Squibb, Pfizer, Novartis, Ipsen, Eisai, Bayer, MSD Oncology, Merck Serono, Roche, AstraZeneca, EUSAPharm, Janssen-Cilag, Asklepios Clinics, Clinic of Oldenburg, AAA/Novartis, Apogepha, Nanobiotix
Consultant or Advisory Role: Bristol-Myers Squibb, Pfizer, Novartis, MSD Oncology, Ipsen, Janssen-Cilag, Onkowissen, CORE2ED
Institutional Research Funding: Novartis, Amgen, MSD Oncology, BMS, Seattle Genetics, Ipsen
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, AstraZeneca
Shilpa Gupta, MD, Associate Editor
Stock and Other Ownership Interests: Nektar, Moderna Therapeutics, BioNTech SE
Honoraria: Bristol Myers Squibb Foundation
Consulting or Advisory Role: Gilead Sciences, Guardant Health, EMD Serono, Pfizer, Merck, Loxo/Lilly, Foundation Medicine, Seattle Genetics, Natera, Bayer
Speakers' Bureau: Bristol-Myers Squibb, Janssen Oncology, Gilead Sciences, Seattle Genetics
Research Funding: Bristol Myers Squibb Foundation, Merck , Roche/Genentech, EMD Serono, QED Therapeutics, Seattle Genetics, gilea, Moderna Therapeutics, Exelixis , Gilead Sciences
Eric Jonasch, MD, Associate Editor
Research Funding: Aravive, Arrowhead, Merck, NiKang, Novartis
Honoraria: Aravive, Aveo, BMS, Calithera, Eisai, Exelixis, Genentech, Ipsen, Merck, Novartis, Pfizer
Bradley Leibovich, MD, Associate Editor
Chair: Kidney Cancer Association Medical Steering Committee
Member: Kidney Cancer Association Board of Directors
Egbert Oosterwijk, MD, Associate Editor
Nothing to disclose
Sumanta Pal, MD, Associate Editor
Travel support: Ipsen, CRISPR, Exelixis
Mamta Parikh, MD, Associate Editor
Consultant: Seagen, Exelixis, Janssen, Oncocyte
Clinical Trials: Karyopharm
Javier Puente, MD, PhD, Associate Editor
Honoraria: Pfizer, Bristol Myers Squibb, Ipsen, AstraZeneca, Roche, MSD Oncology, Janssen-Cilag, Astellas Pharma, EUSA Pharma, Eisai, Pierre Fabre, Sanofi, Bayer
Consultant or Advisory Role: Pfizer, Astellas Pharma, Janssen-Cilag, Merck Sharp & Dohme, Bayer, Roche, Bristol Myers Squibb, Clovis Oncology, Ipsen, Eisai, Sanofi
Research Funding: Astellas Pharma, Pfizer
Travel/Accommodations/Expenses: Pfizer, Roche, Janssen-Cilag, Bristol Myers Squibb, MSD Oncology
Clinical Trials: Pfizer, Bristol Myers Squibb, Ipsen, AstraZeneca, Roche, MSD Oncology, Janssen-Cilag, Astellas Pharma, Eisai, Bayer
Manuela Schmidinger, MD, Associate Editor
Speaker honoraria: Ipsen, Exelisis, Pfizer, EISAI, EUSA, MSD, BMS, Janssen, Astra Zeneca
Consultant: BMS, MSD, EISAI, Exelixis, Ipsen, Pfizer, Astra Teneca
Clinical trials: Exelixis, MSD, EISAI
Sandy Srinivas, MD, Associate Editor
Consultant: Bayer, Merck, Eisai, Novartis, Jansen, Exelixis
Clinical Trials: Seagen, AstraZeneca, Exelixis, Merck, BMS, Novartis
Other: Pfizer dsmc
Last updated: May 29, 2023
